Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in IgA Nephropathy
NCT04342325Phase 1Completed
- Sponsor
- Nagoya University
- Start
- Jun 2020
- Primary completion
- Nov 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in IgA nephropathy (IgAN), sponsored by Nagoya University. Primary endpoint: Incidence of adverse events at 6 weeks. Started Jun 2020; status: completed.
02
Drugs
ADR-001
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04342325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342325.